Brainstorm Cell Therapeutics Inc.(BCLI)Earnings, Financials & Key Ratios
BCLI•NASDAQ
$0.68
$7M mkt cap·0.3× P/E·Price updated May 6, 2026
AboutBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Show more
- Revenue$849K
- EBITDA-$11M+45.9%
- Net Income$12M+167.6%
- EPS (Diluted)2.19+148.9%
- Gross Margin100%
- EBITDA Margin-1349%
- Operating Margin-1377.27%
- Net Margin1369.02%
- Interest Coverage-151.86
BCLI Key Insights
Brainstorm Cell Therapeutics Inc. (BCLI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Healthy 5Y average net margin of 1369.0%
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 38.3% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BCLI Price & Volume
Brainstorm Cell Therapeutics Inc. (BCLI) stock price & volume — 10-year historical chart
Loading chart...
BCLI Growth Metrics
Brainstorm Cell Therapeutics Inc. (BCLI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM147.52%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM10.18%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM46.63%
Return on Capital
10 Years-137.44%
5 Years-172.23%
3 Years-219.56%
Last Year-
BCLI Peer Comparison
Brainstorm Cell Therapeutics Inc. (BCLI) competitors in Regenerative Medicine and Tissue Engineering — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CLLS | 286.73M | 3.95 | -9.63 | 53.97% | -46.97% | -31.79% | 0.70 | |
 FATE | 264.17M | 2.29 | -1.99 | -51.24% | -20.51% | -65.79% | 0.38 | |
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 SNGX | 3.34M | 0.33 | -0.07 | -267.1% | 0.36 | |||
 BIIB | 28.15B | 190.68 | 21.59 | 1.39% | 13.92% | 7.55% | 0.38 | |
 IONS | 12.7B | 76.85 | -32.29 | 33.87% | -30.87% | -58.57% | 5.35 | |
 PRTA | 601.85M | 11.18 | -2.47 | -92.84% | -25.21% | -73% | 0.05 |
Compare BCLI vs Peers
Brainstorm Cell Therapeutics Inc. (BCLI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BCLI Income Statement
Brainstorm Cell Therapeutics Inc. (BCLI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | -366K | 0 | 0 | 0 | 0 | 849K | 849K |
| Revenue Growth % | - | - | - | - | 100% | - | - | - | - | 147.52% |
| Cost of Goods Sold | 77K | 85K | 110K | 366K | 219K | 260K | 285K | 265K | 240K | 111K |
| COGS % of Revenue | - | - | - | -100% | - | - | - | - | 28.27% | - |
| Gross Profit | -77K▲ 0% | -85K▼ 10.4% | -110K▼ 29.4% | -732K▼ 565.5% | -219K▲ 70.1% | -260K▼ 18.7% | -285K▼ 9.6% | -265K▲ 7.0% | 849K▲ 420.4% | 522K▲ 0% |
| Gross Margin % | - | - | - | 200% | - | - | - | - | 100% | 61.48% |
| Gross Profit Growth % | 11.49% | -10.39% | -29.41% | -565.45% | 70.08% | -18.72% | -9.62% | 7.02% | 420.38% | - |
| Operating Expenses | 5.08M | 5M | 14.06M | 23M | 31.68M | 24.54M | 24.82M | 21.17M | 11.45M | 11.9M |
| OpEx % of Revenue | - | - | - | -6284.43% | - | - | - | - | 1349% | - |
| Selling, General & Admin | 2.83M | 4.02M | 5.77M | 5.8M | 9.36M | 9.3M | 10.87M | 10.69M | 7.04M | 6.71M |
| SG&A % of Revenue | - | - | - | -1583.88% | - | - | - | - | 829.45% | - |
| Research & Development | 2.25M | 977K | 8.29M | 17.2M | 22.33M | 15.23M | 13.96M | 10.48M | 4.41M | 5.19M |
| R&D % of Revenue | - | - | - | -4700.55% | - | - | - | - | 519.55% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -5.08M▲ 0% | -5M▲ 1.7% | -14.06M▼ 181.3% | -23M▼ 63.6% | -31.68M▼ 37.8% | -24.54M▲ 22.6% | -24.82M▼ 1.2% | -21.44M▲ 13.6% | -11.69M▲ 45.5% | -11.9M▲ 0% |
| Operating Margin % | - | - | - | 6284.43% | - | - | - | - | -1377.27% | -1401.53% |
| Operating Income Growth % | 40.45% | 1.65% | -181.32% | -63.56% | -37.75% | 22.55% | -1.15% | 13.63% | 45.46% | - |
| EBITDA | -5.01M | -4.91M | -13.95M | -22.84M | -31.46M | -24.28M | -24.54M | -21.17M | -11.45M | -11.68M |
| EBITDA Margin % | - | - | - | 6239.62% | - | - | - | - | -1349% | -1376.21% |
| EBITDA Growth % | 40.75% | 1.84% | -183.94% | -63.67% | -37.78% | 22.84% | -1.06% | 13.71% | 45.91% | 27.14% |
| D&A (Non-Cash Add-back) | 77K | 85K | 110K | 164K | 219K | 260K | 285K | 265K | 240K | 215K |
| EBIT | -4.98M | -4.95M | -13.95M | -23.25M | -31.81M | -24.46M | -24.28M | -17.19M | -11.55M | -11.9M |
| Net Interest Income | 101K | 47K | 0 | 252 | -127K | 82K | 545K | 0 | -77K | -404K |
| Interest Income | 101K | 47K | 0 | 252 | 127 | 82K | 545K | 0 | 0 | 46K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 77K | 450K |
| Other Income/Expense | 101K | 47K | 115K | -252K | -127K | 82K | 545K | 4.25M | 70K | 451K |
| Pretax Income | -4.98M▲ 0% | -4.95M▲ 0.6% | -13.95M▼ 181.7% | -23.25M▼ 66.7% | -31.81M▼ 36.8% | -24.46M▲ 23.1% | -24.28M▲ 0.7% | -17.19M▲ 29.2% | 11.62M▲ 167.6% | -11.45M▲ 0% |
| Pretax Margin % | - | - | - | 6353.28% | - | - | - | - | 1369.02% | -1348.41% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -4.98M▲ 0% | -4.95M▲ 0.6% | -13.95M▼ 181.7% | -23.25M▼ 66.7% | -31.81M▼ 36.8% | -24.46M▲ 23.1% | -24.28M▲ 0.7% | -17.19M▲ 29.2% | 11.62M▲ 167.6% | -11.45M▲ 0% |
| Net Margin % | - | - | - | 6353.28% | - | - | - | - | 1369.02% | -1348.41% |
| Net Income Growth % | 41.31% | 0.6% | -181.66% | -66.71% | -36.8% | 23.12% | 0.74% | 29.18% | 167.61% | 10.18% |
| Net Income (Continuing) | -4.98M | -4.95M | -13.95M | -23.25M | -31.81M | -24.46M | -24.28M | -17.19M | 11.62M | -11.45M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -4.00▲ 0% | -3.92▲ 2.0% | -10.05▼ 156.4% | -13.64▼ 35.7% | -14.09▼ 3.3% | -10.09▲ 28.4% | -9.93▲ 1.6% | -4.48▲ 54.9% | 2.19▲ 148.9% | -1.33▲ 0% |
| EPS Growth % | 41.86% | 2% | -156.38% | -35.72% | -3.3% | 28.39% | 1.59% | 54.88% | 148.88% | 46.63% |
| EPS (Basic) | -4.00 | -3.92 | -10.05 | -13.64 | -14.09 | -10.09 | -9.93 | -4.48 | 2.19 | - |
| Diluted Shares Outstanding | 1.25M | 1.26M | 1.39M | 1.71M | 2.26M | 2.42M | 2.45M | 3.84M | 5.31M | 8.62M |
| Basic Shares Outstanding | 1.25M | 1.26M | 1.39M | 1.7M | 2.26M | 2.42M | 2.45M | 3.84M | 5.31M | 8.62M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BCLI Balance Sheet
Brainstorm Cell Therapeutics Inc. (BCLI) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 10.44M | 9.62M | 10.27M | 3.36M | 43.24M | 23.28M | 3.11M | 1.9M | 385K | 1.51M |
| Cash & Short-Term Investments | 9.99M | 7.76M | 7.06M | 569K | 41.94M | 22.09M | 2.98M | 1.3M | 187K | 824K |
| Cash Only | 547K | 2.48M | 942K | 536K | 37.83M | 18.86M | 772K | 1.3M | 187K | 824K |
| Short-Term Investments | 9.44M | 5.27M | 6.12M | 33K | 4.11M | 3.24M | 2.21M | 0 | 0 | 0 |
| Accounts Receivable | 306K | 672K | 2.01M | 0 | 0 | 0 | 91K | 51K | 63K | 106K |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | 27.08 | 25.37 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 2.63M | 304K | 86K | 0 | 23K | 135K | 585K |
| Total Non-Current Assets | 322K | 1.8M | 958K | 3.17M | 8.02M | 6M | 5.34M | 2.31M | 1.45M | 1.05M |
| Property, Plant & Equipment | 297K | 392K | 651K | 3.13M | 7.96M | 5.95M | 5.32M | 2.1M | 1.24M | 826K |
| Fixed Asset Turnover | - | - | - | -0.12x | - | - | - | - | 0.68x | 0.74x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 16 | 13 | 16 | 13K | 27K | 17K | 9 | 3K | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 185K | 184K | 366K |
| Other Non-Current Assets | 24.98K | 1.41M | 306.98K | 32K | 26K | 27K | 22.99K | 19K | 22K | 472K |
| Total Assets | 10.77M▲ 0% | 11.42M▲ 6.1% | 11.23M▼ 1.7% | 6.53M▼ 41.8% | 51.26M▲ 684.5% | 29.28M▼ 42.9% | 8.45M▼ 71.1% | 4.21M▼ 50.2% | 1.83M▼ 56.5% | 2.57M▲ 0% |
| Asset Turnover | - | - | - | -0.06x | - | - | - | - | 0.46x | 0.34x |
| Asset Growth % | -36.97% | 6.1% | -1.71% | -41.81% | 684.5% | -42.88% | -71.13% | -50.21% | -56.46% | -169.01% |
| Total Current Liabilities | 864K | 5.54M | 6.21M | 17.65M | 11.23M | 6.32M | 8.8M | 7.8M | 8.98M | 8.53M |
| Accounts Payable | 712K | 2.1M | 4.55M | 14.68M | 5.42M | 3.7M | 6.22M | 4.95M | 6.08M | 6M |
| Days Payables Outstanding | 3.38K | 9.02K | 15.09K | 14.64K | 9.03K | 5.19K | 7.97K | 6.82K | 9.25K | 19.3K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 603K | 0 | 101K |
| Deferred Revenue (Current) | 0 | 2.63M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 622K | 714K | 1.9M | 1.07M | 1.06M | 2.24M | 2.35M | 1.68M |
| Current Ratio | 12.09x | 1.74x | 1.65x | 0.19x | 3.85x | 3.69x | 0.35x | 0.24x | 0.04x | 0.04x |
| Quick Ratio | 12.09x | 1.74x | 1.65x | 0.19x | 3.85x | 3.69x | 0.35x | 0.24x | 0.04x | 0.04x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -19.27K |
| Total Non-Current Liabilities | 0 | 0 | 0 | 1.1M | 4.56M | 3.62M | 2.67M | 1.27M | 618K | 95K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 1.1M | 4.56M | 3.62M | 2.67M | 672K | 171K | 664K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 594K | 447K | 1.18M |
| Total Liabilities | 864K | 5.54M | 6.21M | 18.76M | 15.79M | 9.94M | 11.47M | 9.07M | 9.6M | 8.62M |
| Total Debt | 0 | 0 | 0 | 2.37M | 7.22M | 5.08M | 4.09M | 1.27M | 720K | 577K |
| Net Debt | -547K | -2.48M | -942K | 1.83M | -30.61M | -13.78M | 3.32M | -25K | 533K | -247K |
| Debt / Equity | - | - | - | - | 0.20x | 0.26x | - | - | - | -0.10x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.05x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.02x |
| Interest Coverage | - | - | - | - | - | - | - | - | -151.86x | -26.44x |
| Total Equity | 9.9M▲ 0% | 5.88M▼ 40.6% | 5.02M▼ 14.7% | -12.22M▼ 343.7% | 35.46M▲ 390.1% | 19.34M▼ 45.5% | -3.02M▼ 115.6% | -4.86M▼ 61.1% | -7.76M▼ 59.8% | -6.06M▲ 0% |
| Equity Growth % | -29.91% | -40.62% | -14.69% | -343.68% | 390.14% | -45.46% | -115.59% | -61.13% | -59.82% | -300.5% |
| Book Value per Share | 7.95 | 4.65 | 3.61 | -7.17 | 15.71 | 7.98 | -1.23 | -1.27 | -1.46 | -0.70 |
| Total Shareholders' Equity | 9.9M | 5.88M | 5.02M | -12.22M | 35.46M | 19.34M | -3.02M | -4.86M | -7.76M | -6.06M |
| Common Stock | 11K | 11K | 11K | 11K | 12K | 12K | 12K | 13K | 14K | 16K |
| Retained Earnings | -75.12M | -80.08M | -94.02M | -117.28M | -149.09M | -173.54M | -197.82M | -215.01M | -226.64M | -232.4M |
| Treasury Stock | 0 | 0 | 0 | 0 | -116K | -116K | -116K | -116K | -116K | -116K |
| Accumulated OCI | 0 | 0 | 4.41M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BCLI Cash Flow Statement
Brainstorm Cell Therapeutics Inc. (BCLI) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -5.86M | -2.36M | -12.39M | -11.25M | -35.19M | -26.27M | -19.32M | -20.46M | -9.09M | -9.09M |
| Operating CF Margin % | - | - | - | 3072.95% | - | - | - | - | -1071.02% | - |
| Operating CF Growth % | 20.92% | 59.64% | -424.03% | 9.21% | -212.91% | 25.37% | 26.44% | -5.89% | 55.55% | 55.29% |
| Net Income | -4.98M | -4.95M | -13.95M | -23.25M | -31.81M | -24.46M | -24.28M | -17.19M | -11.62M | -11.45M |
| Depreciation & Amortization | 77K | 85K | 110K | 164K | 219K | 260K | 285K | 265K | 240K | 215K |
| Stock-Based Compensation | 635K | 554K | 917K | 789K | 2.56M | 1.37M | 1.68M | 1.49M | 750K | 1.4M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 1.34M | 0 | 0 | 0 |
| Other Non-Cash Items | 121K | 62K | 102K | 0 | 0 | 0 | -1.34M | -4.53M | -147K | -647K |
| Working Capital Changes | -1.71M | 1.89M | 431K | 11.05M | -6.16M | -3.43M | 2.99M | -496K | 1.69M | 1M |
| Change in Receivables | 379K | -2.79M | -238K | 690K | 1.49M | 335K | 1.07M | -475K | 401K | -348K |
| Change in Inventory | 0 | 975K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -824K | 1.08M | 3.12M | 10.13M | -9.26M | -1.72M | 2.52M | -1.27M | 1.13M | 657K |
| Cash from Investing | 5.98M | 3.99M | -1.22M | 5.62M | -4.45M | 323K | 998K | 2.19M | 12K | 12K |
| Capital Expenditures | -103K | -180K | -369K | -473K | -378K | -330K | -29K | -18K | 0 | 0 |
| CapEx % of Revenue | - | - | - | -129.24% | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12K |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 6.08M | 4.17M | -849K | 6.09M | -4.07M | 653K | 0 | 2.21M | 12K | 0 |
| Cash from Financing | 0 | 314K | 12.06M | 5.22M | 76.94M | 6.97M | 238K | 18.98M | 7.97M | 6.84M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -199K |
| Equity Issued (Net) | 0 | 0 | 0 | 1000K | 1000K | 1000K | 238K | 1000K | 1000K | 2.68M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -116K | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 314K | 12.06M | 3.16M | 16.32M | 5K | 0 | 0 | 0 | 1.95M |
| Net Change in Cash | 119K▲ 0% | 1.94M▲ 1526.9% | -1.54M▼ 179.6% | -406K▲ 73.7% | 37.29M▲ 9285.5% | -18.97M▼ 150.9% | -18.08M▲ 4.7% | 713K▲ 103.9% | -1.11M▼ 256.2% | -2.63M▲ 0% |
| Free Cash Flow | -5.96M▲ 0% | -2.54M▲ 57.3% | -12.76M▼ 401.5% | -11.72M▲ 8.1% | -35.57M▼ 203.5% | -26.59M▲ 25.2% | -19.35M▲ 27.2% | -20.48M▼ 5.8% | -9.09M▲ 55.6% | -9.48M▲ 0% |
| FCF Margin % | - | - | - | 3202.19% | - | - | - | - | -1071.02% | -1116.61% |
| FCF Growth % | 20.02% | 57.32% | -401.45% | 8.13% | -203.51% | 25.23% | 27.25% | -5.82% | 55.59% | 34.43% |
| FCF per Share | -4.78 | -2.01 | -9.19 | -6.87 | -15.76 | -10.97 | -7.91 | -5.33 | -1.71 | -1.71 |
| FCF Conversion (FCF/Net Income) | 1.18x | 0.48x | 0.89x | 0.48x | 1.11x | 1.07x | 0.80x | 1.19x | -0.78x | 0.83x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BCLI Key Ratios
Brainstorm Cell Therapeutics Inc. (BCLI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -41.46% | -62.76% | -256.02% | - | -273.75% | -89.25% | -297.38% | - | - | 167.52% |
| Return on Invested Capital (ROIC) | -33.07% | -58.8% | -282.35% | - | - | -353.35% | -634.18% | - | - | 135.99% |
| Gross Margin | - | - | - | 200% | - | - | - | - | 100% | 61.48% |
| Net Margin | - | - | - | 6353.28% | - | - | - | - | 1369.02% | -1348.41% |
| Debt / Equity | - | - | - | - | 0.20x | 0.26x | - | - | - | -0.10x |
| Interest Coverage | - | - | - | - | - | - | - | - | -151.86x | -26.44x |
| FCF Conversion | 1.18x | 0.48x | 0.89x | 0.48x | 1.11x | 1.07x | 0.80x | 1.19x | -0.78x | 0.83x |
| Revenue Growth | - | - | - | - | 100% | - | - | - | - | 147.52% |
BCLI Frequently Asked Questions
Brainstorm Cell Therapeutics Inc. (BCLI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Brainstorm Cell Therapeutics Inc. (BCLI) reported $0.8M in revenue for fiscal year 2024. This represents a 3607% increase from $0.0M in 2001.
Brainstorm Cell Therapeutics Inc. (BCLI) grew revenue by 0.0% over the past year. Growth has been modest.
Brainstorm Cell Therapeutics Inc. (BCLI) reported a net loss of $11.4M for fiscal year 2024.
Dividend & Returns
Brainstorm Cell Therapeutics Inc. (BCLI) had negative free cash flow of $9.5M in fiscal year 2024, likely due to heavy capital investments.
Explore More BCLI
Brainstorm Cell Therapeutics Inc. (BCLI) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates